single component artificial urinary sphincter revision for mechanical failures appears to be safe, efficient and reliable. There is not enough evidence supporting the presence of an association between connector type with the risk of overall device failure.
INTRODUCTION AND OBJECTIVES: AMS implantation is a standard treatment for severe urinary stress incontinence (SUI). According to the literature, patients suffering from Parkinson's disease show adverse continence outcomes after prostate surgery and therefore constitute a challenging cohort for continence surgery. However, there is little known with respect to the results of AUS surgery in these patients. A prospective analysis of our AUS database aims to address this aspect with a focus on surgical and functional outcome METHODS: Since 2009, we prospectively collect data for all patients who undergo AMS 800 implantation due to SUI at our tertiary center. Further follow-up (FU), consisting of pad test, maximal urinary flow rate (Qmax), post void residual urine (PVR), radiography, and standardized questionnaire, is scheduled 6, 24 months and every two years thereafter. Every patient received an urodynamic measurement before AUS implantation. Only patients with normal voiding and storage function of the bladder were considered for AUS implantation. Patients with a history of a stroke or suffering from Parkinson's disease were grouped and compared to non-neurological patients. Primary and secondary endpoints of the study were complication and continence rates respectively. Objective continence was achieved if no safety pad was used per day. Social continence was defined as < 2 pads per day RESULTS: A total of 234 patients were available for analysis. There were 10 patients lost to FU. Median FU was 24 months (IQR 7-36). A total of 24 patients (10.1%) showed a history of a stroke or Parkinson's disease. Comparing these patients to those without a neurological history, significant differences with respect to continence rates are to be seen (p[0.04, p[0.02 and p[0. 093 for objective, subjective and social continence respectively). A significant difference concerning complications in terms of explantation rates was not observed (p[1). A Kaplan-Meier analysis showed no significant difference regarding explantation free survival (log-rank [ 0.526) CONCLUSIONS: AUS implantation shows significantly worse continence rates for patients with a neurological history. This effect can be observed despite the fact that every patient showed normal bladder storage function in the pre-implantation urodynamic evaluation. This study shows that the AUS implantation seems to be a safe and viable treatment for patients with a history of neurological disease. However, they should be counseled for worse continence outcomes 
INTRODUCTION AND OBJECTIVES:
Urethral atrophy has long been suggested as the leading cause of artificial urinary sphincter (AUS) revision. Since introduction of the 3.5 cm AUS cuff to the U.S. market in 2011, precise cuff sizing has been suggested to reduce revisions due to urethral atrophy. We evaluated a large series of reoperative AUS cases in an effort to determine reasons for revision surgery. We hypothesized that appropriate primary use of the 3.5 cm cuff prevents the need for subsequent revision due to urethral atrophy.
METHODS: We retrospectively reviewed our tertiary referral center database of male AUS procedures performed by a single surgeon from 2007-2018. Only AUS revision or replacement procedures were included for analysis. AUS cuff sizes and reasons for reoperation were recorded based on intraoperative findings and cystography. Patients with AUS cuff erosion or lacking follow up were excluded. Success was defined as having no subsequent revisions and continence of 1 pad per day at follow up.
RESULTS: Among 621 evaluable AUS cases, 153 were revisions or replacements. Of these, 113 met inclusion criteria with complete data (mean age 71.2 years, median follow up 9 months [range 1-107]). Urethral atrophy was cited as the cause of AUS failure in 7.96% (9/113) of cases overall, and almost never among those having 3.5 cm cuff placement (1/45, 2.2%). Among those with !4.0 cm cuffs, atrophy was the reason for revision in 8/68 (11.76%). Pressure regulating balloon (PRB) failure was the most frequently cited cause of failure (39/ 113, 34.5 %). Failure of unknown etiology (28/113, 24.8%) and cuffrelated failure (26/113, 23%) were the second and third most frequent causes of failure. Of cuff-related failures, cuff leaks (11/26, 42.3%) and need for proximal cuff relocation (8/26, 30.7%) were cited as most frequent reasons for revision. The overall success rate of these procedures was 54.0% (61/113). Success rates were markedly higher following total system replacements (36/52, 69.2%) compared to subtotal system replacements (22/60, 36.6%) [p<0.001].
CONCLUSIONS: Urethral atrophy is now a rare cause of AUS revision surgery in the current era of 3.5 cm cuff placement. Rather, PRB-related failure is now the leading cause of AUS failure overall. Total AUS system replacement results in better outcomes than subtotal system replacement.
